Animal health company Elanco (NYSE: ELAN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on year to $1.37 billion. Guidance for next quarter’s revenue was better than expected at $1.21 billion at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $0.34 per share was 26.5% above analysts’ consensus estimates.

Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Elanco’s results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, particularly the success of new products like Zenrelia and Credelio Quattro. CEO Jeffrey Simmons noted that “Zenrelia was the largest contributor to second quarter total Elanco growth,” with broad-based gains from innovative treatments and share gains in core categories such as dermatology and parasiticides. Expanded retail availability and increased market penetration further supported volume and pricing strength.

Looking ahead, Elanco’s upgraded guidance is anchored in continued momentum for its innovation portfolio, with increased investments in direct-to-consumer marketing and product launches. Management highlighted the ramp-up of Befrena and anticipated further contributions from the Big 6 innovation products, as well as ongoing productivity gains from the Elanco Ascend cost savings program. CFO Robert VanHimbergen stated, “We are well positioned for continued margin expansion, supported by sustained momentum of our U.S. Pet Health business and early contributions from Elanco Ascend.” Strategic capital allocation remains focused on debt reduction, with expectations for improving operating leverage as new products scale.

Key Insights from Management’s Remarks

Management credited the quarter’s performance to robust innovation-driven growth, strong retail partnerships, and effective commercial execution across pet and farm segments.

• Innovation portfolio momentum: Elanco’s Big 6 innovation products, led by Zenrelia and Credelio Quattro, were primary growth drivers, fueling both U.S. and international revenue and capturing increased market share in dermatology and parasiticides.
• Pet Health channel diversification: The company reported robust sales in both veterinary clinics and retail, with expanded distribution for products like Seresto and the Advantage Family, and new retail partnerships with Costco and Dollar General boosting availability.
• Early success of Befrena: The recent launch of Befrena, a monoclonal antibody for canine dermatology, generated demand that exceeded management’s expectations, with supply constraints expected to ease as manufacturing capacity ramps up into next year.
• Farm Animal segment resilience: Double-digit growth in U.S. Farm Animal was driven by continued demand for products such as Experior and a favorable environment for beef and dairy, while the AHV International acquisition contributed to global ruminant performance.
• Margin expansion and productivity: Gross margin improvement was supported by a favorable product mix, contributions from the Elanco Ascend cost-savings initiative, and disciplined investment in R&D and direct-to-consumer marketing to support new product launches.

Drivers of Future Performance

Management’s outlook centers on sustained innovation, targeted marketing investments, and operational efficiencies to drive revenue growth and further margin improvement.

• Continued product innovation: Elanco anticipates sustained revenue growth from its expanding innovation portfolio, with the Big 6 products expected to double in size over the next three years and new launches like Befrena ramping up market presence by 2027.
• Operational efficiency gains: The Ascend program is projected to deliver significant cost savings and gross margin expansion, with procurement improvements and AI-driven automation supporting long-term profitability and cash flow growth.
• Balanced capital allocation: While debt reduction remains the top priority, management indicated that sub-3x net leverage will unlock additional capital allocation flexibility for M&A and strategic investments, supporting the company’s long-term growth strategy.

Catalysts in Upcoming Quarters

In the quarters ahead, the StockStory team will be watching (1) the pace at which Befrena overcomes supply constraints and scales in the U.S. and international markets, (2) continued market share gains and clinic penetration for Zenrelia and Credelio Quattro, and (3) the impact of Elanco Ascend’s cost savings and automation on margin improvement. Progress on global launches and sustained farm animal segment momentum will also be important markers of ongoing execution.

Elanco currently trades at $26.29, up from $25.59 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.